IBA SA : Full disposal of IBA Molecular by IBA S.A.
14 Décembre 2015 - 08:00AM
Full disposal of IBA Molecular by IBA S.A.
Louvain-la-Neuve,
Belgium - 14 December 2015 - IBA (Ion Beam
Applications S.A.) the world's leading provider of proton therapy
solutions for the treatment of cancer, announces today that it has
signed a definitive agreement for the sale of IBA Molecular
("IBAM"), in which IBA has a 40% stake, to funds advised by CapVest
Partners LP ("CapVest"). IBAM is a joint-venture jointly owned by
IBA (40%) and SK Capital Partners (60%).
This transaction is estimated to
be worth circa EUR 55 million to IBA in cash, representing a
capital gain of circa EUR 30 million based on the current valuation
in IBA's books and is subject to customary closing
conditions. The closing of the transaction is expected by the
end of the first quarter of 2016.
As a reminder, in August, IBA also
announced that the US activities of IBAM had been acquired by
Illinois Health and Science. Today's transaction concerns the
remainder of the IBAM business and its closing will complete IBA's
exit from this business.
Olivier Legrain,
Chief Executive Officer of IBA, commented: "We are pleased to
have completed, together with SK Capital Partners, the disposal of
the assets of IBA Molecular in line with our strategy to divest
non-core assets in order to focus IBA on proton therapy and
associated technologies. We are confident that CapVest is the
ideal acquirer of IBA Molecular and that it will take the Company
to the next level in its development."
***END***
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The Company is the worldwide
technology leader in the field of proton therapy, the most advanced
form of radiation therapy available today. IBA's proton therapy
solutions are flexible and adaptable, allowing customers to choose
from universal full scale proton therapy centers as well as
compact, single room systems. In addition, IBA also has a
radiation dosimetry business and develops particle accelerators for
the medical world and industry.
Headquartered in Belgium and
employing about 1200 people worldwide, IBA has installed systems
across the world, from Europe and the US and to the emerging
markets. IBA is listed on the pan-European stock exchange
EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more
information can be found at: www.iba-worldwide.com
About CapVest
CapVest is an established European
mid-market private equity firm focused
on acquiring market leading companies
supplying essential products and services. The firm places an
emphasis on driving business growth through active management and
has demonstrated consistent success in creating long-term value.
For more information, visit www.capvest.co.uk
For further information please
contact:
IBA
Jean-Marc Bothy
Chief Financial Officer
Tel: +32 10 47 58 90
Thomas
Ralet
Vice-President Corporate Communication
+32 10 47 58 90
communication@iba-group.com
For media and investor
enquiries:
Consilium Strategic Communications
Amber Bielecka, Matthew Neal, Jessica Hodgson and Ivar
Milligan
+44 (0)20 3709 5700
IBA@consilium-comms.com
Rx Communications Group
(US)
Melody Carey
+ 1 917 322 2571
mcarey@RxIR.com
pdf-PR-Molecular-Europe-EN-141215
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
HUG#1973122
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024